{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shah MV"],"funding":["Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic"],"pagination":["1013-1022"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9541522"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["97(8)"],"pubmed_abstract":["Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. We retrospectively analyzed 378 t-MN patients, of which 96 (25.4%, 47 therapy-related acute myeloid leukemia, 1 therapy-related chronic myelomonocytic leukemia, 48 therapy-related myelodysplastic syndrome) received venetoclax. Median interval from t-MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7-12) months, and patients received a median of 3 (IQR 1-4) cycles. The composite complete remission (CRc) rate, median progression-free survival (PFS), and overall survival (OS) were 39.1%, 4"],"journal":["American journal of hematology"],"pubmed_title":["Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms."],"pmcid":["PMC9541522"],"funding_grant_id":["K12CA090628"],"pubmed_authors":["Hiwase D","Alkhateeb HB","Begna KH","Chhetri R","Gangat N","Al-Kali A","Baranwal A","He R","Shah MV","Tiong IS","Greipp PT","Kok CH","Dholakia R","Wei AH","Patnaik MM"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.","description":"Therapy-related myeloid neoplasms (t-MN) are aggressive malignancies in need of effective therapies. The BCL-2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t-MN. We retrospectively analyzed 378 t-MN patients, of which 96 (25.4%, 47 therapy-related acute myeloid leukemia, 1 therapy-related chronic myelomonocytic leukemia, 48 therapy-related myelodysplastic syndrome) received venetoclax. Median interval from t-MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7-12) months, and patients received a median of 3 (IQR 1-4) cycles. The composite complete remission (CRc) rate, median progression-free survival (PFS), and overall survival (OS) were 39.1%, 4","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-22T01:53:30.151Z","creation":"2025-04-05T20:12:10.476Z"},"accession":"S-EPMC9541522","cross_references":{"pubmed":["35560061"],"doi":["10.1002/ajh.26589"]}}